Published in Breast Cancer Res Treat on July 01, 2001
Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism. Eur J Clin Pharmacol (2010) 1.55
Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy. Br J Cancer (2004) 0.85
Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study. Br J Cancer (2005) 0.80
Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer. Br J Cancer (2004) 0.78
Phase II study of gemcitabine, doxorubicin and paclitaxel (GAT) as first-line chemotherapy for metastatic breast cancer: a translational research experience. BMC Cancer (2006) 0.76
A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and gemcitabine in patients with advanced solid tumours. Br J Cancer (2007) 0.75
Phase I and II Study of Gemcitabine and Vinorelbine in Heavily Pretreated Patients with Metastatic Breast Cancer and Review of the Literature. J Cancer (2014) 0.75
Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. N Engl J Med (1981) 7.53
Results of a breast-cancer-surgery trial compared with observational data from routine practice. Lancet (1996) 3.78
Aging and endothelial function in normotensive subjects and patients with essential hypertension. Circulation (1995) 3.19
Breast conservation is the treatment of choice in small breast cancer: long-term results of a randomized trial. Eur J Cancer (1990) 3.01
Radiotherapy after breast-conserving surgery in small breast carcinoma: long-term results of a randomized trial. Ann Oncol (2001) 2.89
Breast conservation is a safe method in patients with small cancer of the breast. Long-term results of three randomised trials on 1,973 patients. Eur J Cancer (1995) 2.30
Ten year results of a randomised trial comparing two conservative treatment strategies for small size breast cancer. Eur J Cancer (1998) 1.68
The beta3-adrenoceptor agonist SR58611A ameliorates experimental colitis in rats. Neurogastroenterol Motil (2008) 1.44
Outcome of laparoscopic transabdominal preperitoneal inguinal hernia repair. Surg Laparosc Endosc (1998) 1.40
Observation of B(0)(s)-->Psi(2S)Phi and measurement of the ratio of branching fractions Beta(B(0)(s)-->Psi(2S)Phi)/Beta(B(0)(s)-->J/PsiPhi). Phys Rev Lett (2006) 1.40
A rare laparoscopic diagnosis in acute abdominal pain: torsion of epiploic appendix. Surg Laparosc Endosc (1997) 1.39
Presence of a non-adrenergic inhibitory system in the human colon. Gut (1968) 1.35
Precision top-quark mass measurement at CDF. Phys Rev Lett (2012) 1.30
Lymphoid infiltration as a prognostic variable for early-onset breast carcinomas. Clin Cancer Res (1997) 1.29
Conservative treatment of early breast cancer. Long-term results of 1232 cases treated with quadrantectomy, axillary dissection, and radiotherapy. Ann Surg (1990) 1.28
Biologic and clinicopathologic factors as indicators of specific relapse types in node-negative breast cancer. J Clin Oncol (1995) 1.27
Review article: molecular, pathological and therapeutic features of human enteric neuropathies. Aliment Pharmacol Ther (2008) 1.24
Measurement of the cross section for prompt isolated diphoton production using the full CDF run II data sample. Phys Rev Lett (2013) 1.22
Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe. Ann Oncol (2006) 1.21
Geographical variations of place of death among Italian communities suggest an inappropriate hospital use in the terminal phase of cancer disease. Public Health (2000) 1.19
Conservative treatment of breast cancer. A trial in progress at the Cancer Institute of Milan. Cancer (1977) 1.16
In-situ breast cancer: the EORTC consensus meeting. Lancet (1989) 1.13
Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients. Ann Oncol (2001) 1.12
Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors. Am J Clin Oncol (2000) 1.12
Measurement of the WW + WZ production cross section using the lepton + jets final state at CDF II. Phys Rev Lett (2010) 1.12
First observation of the decay Bs0-->Ds-Ds+ and measurement of its branching ratio. Phys Rev Lett (2008) 1.11
Agenesis of the horizontal segment of the left portal vein demonstrated by magnetic resonance imaging including phase-contrast magnetic resonance venography. Eur Radiol (2000) 1.10
Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib. Br J Cancer (2008) 1.10
ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin. Br J Cancer (2013) 1.10
Which therapy for unexpected phyllode tumour of the breast? Eur J Cancer (1992) 1.10
Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients. Clin Cancer Res (2000) 1.09
p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J Clin Oncol (1996) 1.09
Evidence for a particle produced in association with weak bosons and decaying to a bottom-antibottom quark pair in higgs boson searches at the tevatron. Phys Rev Lett (2012) 1.08
Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer. Br J Cancer (2011) 1.07
Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer. J Clin Oncol (1997) 1.07
Measurement of sigma chi c2 B(chi c2-->J/psi gamma)/sigma chi c1 B(chi c1 -->J/psi gamma) in pp collisions at square root s=1.96 TeV. Phys Rev Lett (2007) 1.07
Baseline elevated leukocyte count in peripheral blood is associated with poor survival in patients with advanced non-small cell lung cancer: a prognostic model. J Cancer Res Clin Oncol (2008) 1.07
Precise measurement of the W-boson mass with the CDF II detector. Phys Rev Lett (2012) 1.06
Inflammatory cancer of the breast: analysis of 114 cases. J Surg Oncol (1981) 1.05
Direct measurement of the W production charge asymmetry in pp collisions at square root s=1.96 TeV. Phys Rev Lett (2009) 1.04
Search for long-lived massive charged particles in 1.96 TeV pp collisions. Phys Rev Lett (2009) 1.03
Measurement of d sigma/dM and forward-backward charge asymmetry for high-mass Drell-Yan e(+)e(-) pairs from pp macro collisions at square root of s = 1.8 TeV. Phys Rev Lett (2001) 1.02
Functional hepatic flow and Doppler-assessed total hepatic flow in control subjects and in patients with cirrhosis. J Hepatol (1995) 1.02
Effect of suramin on human prostate cancer cells in vitro. J Urol (1991) 1.00
Periodontal tissue disposition of azithromycin in patients affected by chronic inflammatory periodontal diseases. J Periodontol (1999) 1.00
Proceedings: Prostaglandins in human colonic carcinoma. Gut (1975) 1.00
An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients. Ann Oncol (2011) 1.00
Observation of Bs(0)-Bs(0) oscillations. Phys Rev Lett (2006) 1.00
Frequency and biochemical expression of C282Y/H63D hemochromatosis (HFE) gene mutations in the healthy adult population in Italy. J Hepatol (2001) 0.99
Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer. Ann Oncol (2002) 0.99
Characterization of a novel mechanism accounting for the adverse cholinergic effects of the anticancer drug irinotecan. Br J Pharmacol (2001) 0.98
Geranylgeraniol overcomes the block of cell proliferation by lovastatin in C6 glioma cells. J Neurochem (1998) 0.98
Suramin inhibits bFGF-induced endothelial cell proliferation and angiogenesis in the chick chorioallantoic membrane. Br J Cancer (1993) 0.97
Cyclophosphamide-methotrexate 'metronomic' chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation. Ann Oncol (2005) 0.97
Search for large extra dimensions in final states containing one photon or jet and large missing transverse energy produced in pp collisions at square root[s]=1.96 TeV. Phys Rev Lett (2008) 0.97
Polarizations of J/psi and psi(2S) mesons produced in pp collisions at square root s = 1.96 TeV. Phys Rev Lett (2007) 0.96
Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells. Br J Cancer (2005) 0.96
In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients. Br J Cancer (2006) 0.96
Cardiotoxicity of epirubicin/paclitaxel-containing regimens: role of cardiac risk factors. J Clin Oncol (1999) 0.96
Measurement of the top-quark mass in all-hadronic decays in pp collisions at CDF II. Phys Rev Lett (2007) 0.95
Inhibition of human immunodeficiency virus (HIV-1) infection in human peripheral blood leucocytes-SCID reconstituted mice by rapamycin. Clin Exp Immunol (2009) 0.95
Role of cyclooxygenases 1 and 2 in the modulation of neuromuscular functions in the distal colon of humans and mice. Gut (2005) 0.95
Geranylgeranyl diphosphate-based inhibitors of post-translational geranylgeranylation of cellular proteins. J Med Chem (1996) 0.95
Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide. Ann Oncol (2000) 0.95
Periodontal tissue disposition of azithromycin. J Periodontol (1997) 0.95
Hematologic toxicity of immunosuppressive treatment. Transplant Proc (2004) 0.94
Measurement of the strong coupling constant from inclusive jet production at the Tevatron pp collider. Phys Rev Lett (2002) 0.94
The actions of atropine, tropenziline and N-butyl hyoscine bromide on the isolated distal colon of the guinea-pig: a comparison of their activities and mechanisms of action. J Pharm Pharmacol (1969) 0.94
Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma. Br J Cancer (2005) 0.94
Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients. J Clin Oncol (2001) 0.94
Gastrointestinal mucormycosis and liver transplantation; a case report and review of the literature. Transpl Int (1999) 0.94
Cyclins of phases G1, S and G2/M are overexpressed in aneuploid mammary carcinomas. Cytometry (2000) 0.94
The effect of lipoproteins on endothelial nitric oxide synthase is modulated by lipoperoxides. Eur J Clin Invest (2003) 0.94
Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer. J Nucl Med (1998) 0.93
Search for gluinos and scalar quarks in pp collisions at square root[s] = 1.8 TeV using the missing energy plus multijets signature. Phys Rev Lett (2002) 0.93
Gemcitabine monotherapy in elderly patients with advanced non-small cell lung cancer: a multicenter phase II study. Lung Cancer (2000) 0.93
Experiments on the mechanism of action of caerulein at the level of the guinea-pig ileum and colon. Agents Actions (1970) 0.93
Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer. Ann Oncol (2001) 0.93